EOCN

Galmed Pharmaceuticals Ltd. EOCN

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $2.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$62.9K total
CITADEL ADVISORS LLC
$48.3K+663.1%
XTX Topco Ltd
$8.4K-33.0%
TWO SIGMA SECURITIES, LLC
$6.1K-8.0%
SBI Securities Co., Ltd.
$37+312.5%
MORGAN STANLEY
$31-64.3%
WELLS FARGO & COMPANY/MN
$240.0%
HRT FINANCIAL LP
$23New
Federation des caisses Desjardins du Quebec
$80.0%
Allworth Financial LP
$20.0%
UBS Group AG
$2-99.9%
OSAIC HOLDINGS, INC.
$20.0%
ZRC WEALTH MANAGEMENT, LLC
$10.0%
ROYAL BANK OF CANADA
$0New
TSFG, LLC
$00.0%
See all 14 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q4 2025
EDGAR

EPS (Diluted)

Q4 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/EOCN

Earnings Per Share

13fpro.ai/company/EOCN

Loading ratio trend…

EOCN key financials by period

Reported revenue, net income and operating margin by fiscal year, from Galmed Pharmaceuticals Ltd.'s annual filings on SEC EDGAR.

Galmed Pharmaceuticals Ltd. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2018$2.0M$-9.9M—
FY 2017$1.1M$-12.3M—
FY 2016$467.0K$-17.0M—
Source: EOCN filings on SEC EDGAR →

About Galmed Pharmaceuticals Ltd. (EOCN): stock profile, AI score and financials

Galmed Pharmaceuticals Ltd. (EOCN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. EOCN is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $2.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of EOCN by reported 13-F value include CITADEL ADVISORS, XTX Topco Ltd, TWO SIGMA SECURITIES, based on the most recent SEC filings. EOCN trades on the Nasdaq exchange and files with the SEC under CIK 1595353. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EOCN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Galmed Pharmaceuticals Ltd. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1595353 →